[ad_1]
Sharps Technology, Inc. has recently announced a significant Sales Agreement with a U.S.-based pharma company for customized 10mL SoloGard syringes. This agreement is set to generate at least $50 million in revenue and has completely sold out the current manufacturing capacity for these syringes. The company also signed agreements with a European medical supply company for the purchase of 1mL and 3mL SecureGard inventory. This will lead to new production orders in 2025, consuming all available production capacity. The demand for Sharps’ injection solutions is rapidly growing, driving the need for expansion in their Hungary facility.
The company’s Hungary facility is expected to see solid revenue growth, with revenue targets of over $5 million in 2025, $15 million in 2026, and $20 million in 2027. Additionally, Sharps is working on finalizing the acquisition of manufacturing assets in South Carolina. The company also recently regained compliance with NASDAQ’s listing rules after working to meet remediation requirements.
Sharps Technology specializes in innovative drug delivery systems focusing on low waste and ultra-low waste syringe technologies. The company is well-positioned to respond to upcoming opportunities and looks forward to a bright future. For more information, visit Sharps Technology’s website. Contact RedChip Companies for investor relations inquiries.
Source
Photo credit www.globenewswire.com
